You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

CLINICAL TRIALS PROFILE FOR BETA CAROTENE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Beta Carotene

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT02131194 ↗ The Post-Vitrectomy Lenstatin™ Study Completed Lenstatin LLC N/A 2014-06-01 To determine the efficacy of Lenstatin™, an over-the-counter nutritional supplement, in inhibiting the progression of nuclear cataract in eyes after pars plana vitrectomy.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Beta Carotene

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000152 ↗ Randomized Trial of Beta-Carotene and Macular Degeneration Unknown status National Eye Institute (NEI) Phase 3 1982-04-01 To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
NCT00000157 ↗ Randomized Trial of Aspirin and Cataracts in U.S. Physicians Terminated National Eye Institute (NEI) Phase 3 1982-04-01 To determine whether 325 mg of aspirin taken on -alternate days reduces the risk of developing cataract among male U.S. physicians who were aged 40 to 84 in 1982. To identify potential risk factors for cataract development, such as age, blood pressure, blood cholesterol, height, diabetes, medication use, and history of previous eye trauma or surgery.
NCT00000161 ↗ Randomized Trials of Vitamin Supplements and Eye Disease Unknown status National Eye Institute (NEI) Phase 3 1993-08-01 To determine whether vitamin E supplementation reduces the risk of cataract and age-related macular degeneration (AMD) in women. To determine whether vitamin C supplementation reduces the risk of cataract and AMD in women. To determine whether beta-carotene supplementation reduces the risk of cataract and AMD in women. To determine whether alternate day, low-dose aspirin reduces the risk of cataract and AMD in women. To identify potential risk factors for cataract and AMD including cigarette smoking, alcohol intake, blood pressure, blood cholesterol, cardiovascular disease, height, body mass index, and diabetes.
NCT00000500 ↗ Physicians' Health Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1981-09-01 To assess the effect on cardiovascular mortality of alternate-day consumption of 325 milligrams of aspirin and, secondarily, the effect on cancer incidence of alternate-day consumption of 50 milligrams of beta-carotene.
NCT00000500 ↗ Physicians' Health Study Completed Brigham and Women's Hospital Phase 3 1981-09-01 To assess the effect on cardiovascular mortality of alternate-day consumption of 325 milligrams of aspirin and, secondarily, the effect on cancer incidence of alternate-day consumption of 50 milligrams of beta-carotene.
NCT00000539 ↗ Arterial Disease Multifactorial Intervention Trial (ADMIT) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1992-09-01 To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Beta Carotene

Condition Name

Condition Name for Beta Carotene
Intervention Trials
Cardiovascular Diseases 4
Heart Diseases 4
Macular Degeneration 3
Cataract 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Beta Carotene
Intervention Trials
Macular Degeneration 4
Heart Diseases 4
Cardiovascular Diseases 4
Cataract 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Beta Carotene

Trials by Country

Trials by Country for Beta Carotene
Location Trials
United States 49
Italy 2
Israel 2
United Kingdom 2
Bangladesh 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Beta Carotene
Location Trials
Maryland 3
Florida 3
Texas 3
New York 2
Colorado 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Beta Carotene

Clinical Trial Phase

Clinical Trial Phase for Beta Carotene
Clinical Trial Phase Trials
Phase 4 3
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Beta Carotene
Clinical Trial Phase Trials
Completed 18
Unknown status 5
Withdrawn 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Beta Carotene

Sponsor Name

Sponsor Name for Beta Carotene
Sponsor Trials
National Eye Institute (NEI) 5
National Heart, Lung, and Blood Institute (NHLBI) 5
Sheba Medical Center 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Beta Carotene
Sponsor Trials
Other 50
NIH 14
Industry 8
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.